Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Procter & Gamble HealthBOM:500126 -0.76%86 Interest Coverage is 616.29 as of Mar. 2026, which is 94% below its 10-year median of 10,000.00. GuruFocus rates BOM:500126 with a GF Score™ of 86/100 and a GF Value™ of ₹6,049.27 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 687 Drug Manufacturers companies, Procter & Gamble Health ranks better than 92.14% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Procter & Gamble Health's
Operating Income
for the
three
months ended in Mar. 2026 was ₹1,294 Mil. Procter & Gamble Health's Interest Expense for the
three
months ended in Mar. 2026 was ₹-2 Mil.
Procter & Gamble Health's interest coverage for the quarter that ended in Mar. 2026 was 616.29.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Procter & Gamble Health Ltd has enough cash to cover all of its debt. Its financial situation is stable.
The historical rank and industry rank for Procter & Gamble Health's Interest Coverage or its related term are showing as below:
BOM:500126'
s Interest Coverage Range Over the Past 10 Years
Min: 281.35 Med: No Debt Max: No Debt
Current: 787.4
BOM:500126's Interest Coverage is ranked better than 92.14% of 687
companies
in the Drug Manufacturers industry
Industry Median: 12.75
vs BOM:500126: 787.40
Procter & Gamble Health (BOM:500126) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Procter & Gamble Health Interest Coverage Related Terms
Procter & Gamble Health Interest Coverage Historical Data
* Premium members only.
The historical data trend for Procter & Gamble Health's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
BOM:500126 vs ZTS, UTHR: Interest Coverage Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Procter & Gamble Health's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Procter & Gamble Health Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Procter & Gamble Health's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Procter & Gamble Health's Interest Coverage falls into.
Procter & Gamble Health Interest Coverage Calculation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Procter & Gamble Health (BOM:500126) has a Interest Coverage of 616.29 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Procter & Gamble Health and its competitors. This is 94% below median its historical median of 10,000.00. Over the past decade, Procter & Gamble Health's Interest Coverage has ranged from 281.35 to 10,000.00. According to the industry distribution chart, Procter & Gamble Health ranks #54 out of 687 companies in the Drug Manufacturers industry, placing it in the top 7.9%.
Is Procter & Gamble Health's Interest Coverage too high?
Procter & Gamble Health's current Interest Coverage of 616.29 is 94% below median its 10-year median of 10,000.00. Over the past 10 years, this metric has ranged from a low of 281.35 to a high of 10,000.00. The Drug Manufacturers industry median Interest Coverage is 12.75. Procter & Gamble Health's value of 616.29 is 4733.6% above this industry median. Based on the distribution chart, Procter & Gamble Health ranks #54 out of 687 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Procter & Gamble Health has a GF Score™ of 86/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Procter & Gamble Health's Interest Coverage compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Procter & Gamble Health ranks #54 out of 687 companies for Interest Coverage. This places Procter & Gamble Health in the top 8% of its industry — outperforming the majority of peers. The industry median Interest Coverage is 12.75. Procter & Gamble Health's value of 616.29 is 4733.6% above this benchmark. Historically, Procter & Gamble Health's own Interest Coverage has ranged from 281.35 to 10,000.00 over the past decade. While the company's 10-year median is 10,000.00 vs. the industry median of 12.75, Procter & Gamble Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.75, based on 687 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Procter & Gamble Health's current Interest Coverage of 616.29 is 4733.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Procter & Gamble Health and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Procter & Gamble Health's current Interest Coverage is 616.29, which is 94% below median its own 10-year median of 10,000.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Procter & Gamble Health stock overvalued right now?
Based on GuruFocus' analysis, Procter & Gamble Health (BOM:500126) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹6,049.27, compared to a current price of ₹6,797.90 — trading 12.4% above its estimated fair value. The current Interest Coverage is 616.29, which is 94% below median its 10-year median of 10,000.00 and 4733.6% above the Drug Manufacturers industry median of 12.75. Procter & Gamble Health's overall GF Score™ is 86/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Procter & Gamble Health (BOM:500126), the current Interest Coverage is 616.29 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Procter & Gamble Health (BOM:500126) Overvalued in 2026?
Based on GuruFocus' analysis, Procter & Gamble Health stock appears to be overvalued.
The current stock price of ₹6,797.90 is trading 12.4% above its estimated GF Value™ of ₹6,049.27.
GuruFocus considers Procter & Gamble Health to be Modestly Overvalued.
Key valuation signals for BOM:500126:
Interest Coverage: 616.29 (94% below median its 10-year median of 10,000.00)
GF Value™: ₹6,049.27 vs. price of ₹6,797.90 (12.4% above fair value)
Industry Position: 4733.6% above the Drug Manufacturers median (#54 of 687)
No single metric tells the full story. See the BOM:500126 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Procter & Gamble Health Ltd is an India based pharmaceutical company engaged in manufacturing and selling of healthcare products, viz., vitamins, minerals and supplements. Patients are end consumers of the products. The Company's distribution channels (direct & indirect), inter alia, include distributors, health care professionals, pharmacies and chemists. Cosome, Evion, Neurobion, Nasivion, Polybion, Livogen and Seven Seas are some of the brands of the company. The geographical segments include sales in India and exports.
86GF Score
Get the complete analysis for BOM:500126
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:500126 has been successfully added to your 
